CLRB - Cellectar Biosciences, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.1000
-0.0500 (-2.33%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close2.1500
Open2.1400
Bid2.0600 x 900
Ask2.1000 x 800
Day's Range2.0700 - 2.1400
52 Week Range1.2200 - 7.1500
Volume121,216
Avg. Volume476,741
Market Cap19.732M
Beta (3Y Monthly)1.23
PE Ratio (TTM)N/A
EPS (TTM)-4.1840
Earnings DateAug 8, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.20
Trade prices are not sourced from all markets
  • GlobeNewswire12 days ago

    Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma

    FLORHAM PARK, N.J., July 09, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

  • GlobeNewswire2 months ago

    Cellectar Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131

    FLORHAM PARK, N.J., May 21, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

  • GlobeNewswire2 months ago

    Cellectar Biosciences Announces Closing of $10.0 Million Financing

    Cellectar Biosciences, Inc. (CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it closed its previously announced financing for gross proceeds of $10 million.  In a registered direct offering, Cellectar issued 1,982,000 shares of common stock at an offering price of $2.50 per share. In a concurrent private placement, Cellectar issued to the purchasers of our common stock in the registered direct offering, Series F warrants to purchase an aggregate of 1,982,000 shares of common stock.

  • ETF Trends2 months ago

    5 Biotech Stocks to Watch in the Second Half of 2019

    Biotechnology stocks can generate strong opportunities, as they are riddled with catalytic events through the development, regulatory and commercial processes. Catalyst Pharmaceuticals  CPRX [NSC] – $3.14  has had an incredibly strong start to the year. After receiving FDA approval for Firdapse back in November of 2018 for adults with Lambert-Eaton Myasthenic Syndrome (LEMS), Catalyst has pleased investors with its commercialization efforts and the potential revenue that the treatment would generate.

  • GlobeNewswire2 months ago

    Cellectar Biosciences Announces $10.0 Million Financing

    Cellectar Biosciences, Inc. (CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has entered into definitive agreements with institutional investors to purchase approximately $5.0 million in a registered direct offering of 1,982,000 common shares and approximately $5.0 million in a concurrent private placement of 2,018,000 common shares.  In conjunction with the offerings, the company issued 4,000,000 unregistered warrants to purchase common stock.

  • GlobeNewswire2 months ago

    CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced initial results from Cohort 6 in the Company’s ongoing Phase 1 clinical study with CLR 131 in Relapsed or Refractory Multiple Myeloma (R/R MM).  The 37.5mCi/m2 fractionated dose was determined to be safe and tolerable by the independent Data Monitoring Committee (DMC). Following the determination, the Company has initiated a Cohort 7 utilizing a 40mCi/m2 fractionated dose (20mCi/m2 dose on day 1 and day 8).

  • GlobeNewswire2 months ago

    Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma

    FLORHAM PARK, N.J., May 13, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

  • GlobeNewswire2 months ago

    Cellectar Reports First Quarter 2019 Financial Results and Provides a Corporate Update

    Reported positive top-line results from relapsed/refractory multiple myeloma cohort in ongoing Phase 2 clinical study of CLR 131 Announced median overall survival rate of 22.

  • Benzinga3 months ago

    5 Biotech Stocks With Near-Term Catalysts Ahead

    The biotechnology space is an exciting one with incredible potential for investors. One strategy that many have found success with in the biotech investing space is making moves around catalysts. This involves looking for companies with data readouts, PDUFA dates, and other upcoming releases that will likely move the needle for the stock.

  • Cellectar Biosciences, Inc. (NASDAQ:CLRB): Are Analysts Right About The Drop In Earnings?
    Simply Wall St.3 months ago

    Cellectar Biosciences, Inc. (NASDAQ:CLRB): Are Analysts Right About The Drop In Earnings?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Cellectar Biosciences, Inc.'s (NASDAQ:CLRB) latest earnings announcement in December 2018 reveal...

  • GuruFocus.com3 months ago

    5 Oncology Companies That Are Set to Run

    The cancer treatment market is a massive one, and the companies that produce these treatments often make strong investment opportunities. With so much financial opportunity in the space and several areas with medical need, oncology stocks tend to be met with heavy investor interest. Warning! GuruFocus has detected 6 Warning Signs with SGEN.

  • GlobeNewswire4 months ago

    FDA Grants Exemption to Import Alert for Cellectar’s CLR 131 in Pediatric and Adolescent Patients

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted an exemption to the Import Alert placed on the Centre for Probe Development and Commercialization (CPDC) for the use of CLR 131 in connection with the company’s pediatric IND. This exemption will allow Cellectar to immediately begin enrolling patients in its Phase 1 pediatric study for the treatment of select relapsed or refractory solid tumors including neuroblastoma, lymphomas and malignant brain tumors.

  • GlobeNewswire5 months ago

    Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update

    FLORHAM PARK, N.J., Feb. 26, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

  • GlobeNewswire5 months ago

    Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced additional positive top-line results from its ongoing Phase 2 clinical study of CLR 131, the company’s lead product candidate. In the relapse refractory multiple myeloma cohort, CLR 131 achieved a 30% overall response rate in the first 10 evaluable patients.

  • GlobeNewswire5 months ago

    Cellectar Biosciences to Present at the Annual BIO CEO & Investor Conference

    FLORHAM PARK, N.J., Feb. 05, 2019 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

  • GlobeNewswire6 months ago

    Cellectar Biosciences to Present at NobleConXV, Noble Capital Markets’ Fifteenth Annual Investor Conference

    FLORHAM PARK, N.J., Jan. 23, 2019 -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

  • What Kind Of Shareholders Own Cellectar Biosciences, Inc. (NASDAQ:CLRB)?
    Simply Wall St.6 months ago

    What Kind Of Shareholders Own Cellectar Biosciences, Inc. (NASDAQ:CLRB)?

    If you want to know who really controls Cellectar Biosciences, Inc. (NASDAQ:CLRB), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk Read More...

  • GlobeNewswire6 months ago

    Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma

    FLORHAM PARK, N.J., Jan. 07, 2019 -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

  • GlobeNewswire7 months ago

    Cellectar Biosciences to Present at the Biotech Showcase

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces that James Caruso, president and chief executive officer of Cellectar Biosciences, will present a company overview at the Biotech Showcase on Monday, January 7, 2019 at 10:00am Pacific Time.  The conference will be held at the Hilton San Francisco Union Square January 7-9, 2019. Cellectar's product candidates are built upon a patented delivery and retention platform that utilizes optimized phospholipid ether-drug conjugates (PDCs™) to target cancer cells. The PDC platform selectively delivers diverse oncologic payloads to cancerous cells and cancer stem cells, including hematologic cancers and solid tumors.

  • GlobeNewswire7 months ago

    Cellectar Granted Japanese Patent for CLR 131

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces that the Japan Patent Office has granted the patent titled “Phospholipid Analogs as Diapeutic Agents and Methods of Use Thereof” with application number 2016135920.  The patent provides composition of matter and use protection for the company’s proprietary phospholipid ether (PLE) analogs and specifically CLR 131 in breast, brain, leukemias and a variety of other cancers.

  • GlobeNewswire8 months ago

    Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma

    FLORHAM PARK, N.J., Dec. 04, 2018 -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and.

  • Analysts Take Action on Health Care Stocks
    GuruFocus.com8 months ago

    Analysts Take Action on Health Care Stocks

    The analyst established a price target of $174 per share, which represents 38.3% upside from the share price of $125.8 at market close on Tuesday. The share price has increased 46% over the 52 weeks of trading through Nov. 20. Warning! GuruFocus has detected 6 Warning Signs with BGNE.

  • GlobeNewswire8 months ago

    Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update

    Cellectar Biosciences, Inc. (CLRB) (“Cellectar” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today reported financial results for the three and nine months ended September 30, 2018 and provided a business update. Announced that the U.S. Food and Drug Administration has granted an exemption to the Import Alert for CLR 131 in all hematology indications, effective immediately.  The company continues to work with the appropriate division of the FDA to obtain an exemption for its pediatric program, evaluating CLR 131 in multiple childhood cancers with significant unmet medical need.

  • GlobeNewswire8 months ago

    Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted an exemption to the Import Alert placed on the Centre for Probe Development and Commercialization (CPDC), the sole supplier of the CLR 131. The exemption for CLR 131 is effective immediately for all hematology studies and, in response, Cellectar is preparing to dose patients in the second fractionated dose cohort of the Phase 1 relapsed refractory (R/R) multiple myeloma study and the Phase 2 study for R/R hematologic malignancies.